Compare Amylx Pharmaceuticals Inc (AMLX) vs Monster Beverage Corp (MNST) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Amylx Pharmaceuticals Inc vs Monster Beverage Corp — how do they compare? Amylx Pharmaceuticals Inc trades at $17.77 (market cap $1.98B), while Monster Beverage Corp trades at $98.39 (market cap $95.25B). The key difference: Monster Beverage Corp is far larger — about 48.1× Amylx Pharmaceuticals Inc's market cap, and Monster Beverage Corp is trading nearer its 52-week high, Amylx Pharmaceuticals Inc nearer its low. Which is the better fit depends on your goals.
| AMLX | MNST | |
|---|---|---|
Market Cap | $1.98B | $95.25B |
Sector | Health | Consumer Staples |
52-Week High | $18.70 | $97.64 |
52-Week Low | $7.64 | $58.65 |
Enterprise Value | $1.70B | $93.54B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AMLX trades at $17.77, down 3.32% today, with a bullish technical signal from moving averages and strong analyst support. The company is in a pivotal phase with key Phase 3 data for avexitide expected in Q3 2026, targeting a potential 2027 launch. Financially, it shows significant losses with negative ROE and ROA, but cash flow from financing activities provides runway. Recent news highlights clinical progress and conference presentations, alongside ongoing class action settlement discussions.
The outlook hinges on successful clinical trial outcomes, particularly avexitide's Phase 3 readout, which could drive substantial upside toward the $30.50 consensus price target. However, high execution risk, persistent cash burn, and legal overhangs pose threats to near-term stability. Investor sentiment remains cautiously optimistic given the 90.9% buy rating from analysts, but the stock is speculative until profitability milestones are achieved.
Monster Beverage (MNST) trades at $97.39, up 0.87% today, showing strong momentum after recent earnings beats. The stock exhibits a bullish technical trend, with moving averages supporting further upside, while oscillators are neutral. Fundamentally, the company reported robust revenue growth to $8.29 billion in 2025, with a net income margin of 23.11%, and announced a 2-for-1 stock split effective August 2026, reflecting confidence in future performance.
The outlook remains positive given consistent earnings outperformance and international expansion, but high valuation multiples like a P/E of 47.05 pose risks if growth slows. Investor sentiment is buoyed by analyst consensus favoring buys, though competitive pressures and macroeconomic factors warrant caution for sustained gains.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Amylx Pharmaceuticals Inc
Amylyx Pharmaceuticals is a biopharmaceutical firm focused on developing therapies for rare diseases. Its pipeline includes treatments for conditions like post-bariatric hypoglycemia and congenital hyperinsulinism.
Read more on AMLX →About Monster Beverage Corp
Monster Beverage is a leader in the energy drink subsegment of the beverage industry. The Monster trademark anchors the portfolio, and notable offerings include Monster Energy and Monster Ultra. The firm has also started to incubate new trademarks for emerging enclaves of the energy space, like Reign in performance energy. It is primarily a brand owner, outsourcing most of its manufacturing processes to third-party copackers. It primarily uses the Coca-Cola bottling system for distribution after a strategic agreement in which Coke became Monster's largest shareholder (nearly 20%) and that also included the exchange of certain businesses between the two firms. Most of Monster's revenue is generated in the United States, though international geographies are increasing in the mix.
Read more on MNST →
